Prelude Capital Management’s Revolution Medicines RVMD Stock Holding History

Prelude Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Sell	10,997 -6,076	-36%	-$888K	0.15%	172
2026 Q1	$1.66M	Buy	+17,073	New	+$1.72M	0.13%	197
2025 Q4	–	Sell	-20,000	Closed	-$934K	–	1523
2025 Q3	$934K	Buy	+20,000	New	+$783K	0.07%	319
2023 Q3	–	Sell	-12,100	Closed	-$324K	–	1324
2023 Q2	$324K	Buy	+12,100	New	+$297K	0.02%	607

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Prelude Capital Management's RVMD Position: Q2 2026 in Review

Prelude Capital Management reduced its Revolution Medicines (RVMD) stake by 36% in Q2 2026, selling an estimated $888K and leaving 10,997 shares worth $2.06M. The position accounts for 0.15% of the portfolio, ranked #172.

Prelude Capital Management first reported a position in RVMD in Q2 2023 and has held it in 4 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Prelude Capital Management held 10,997 shares of Revolution Medicines worth $2.06M as of Q2 2026.
Prelude Capital Management sold 6,076 Revolution Medicines shares in Q2 2026, an estimated $888K.
Revolution Medicines made up 0.15% of Prelude Capital Management's portfolio in Q2 2026, its #172 holding.
Prelude Capital Management first reported a position in Revolution Medicines in Q2 2023 and has held it in 4 quarters since.
693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.